SEK 11.04
-0.08 (-0.72%)
SEK · as of 2026-08-20 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VICO.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 observational · 9 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.NCT06588686To evaluate the efficacy of buloxibutid compared to placebo in participants with IPF as assessed by FVCRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Buloxibutid, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 378 | May 2027 | ≤ 282 d | 2026-08-17 |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022results2025-05-23Number of Participants With Adverse Events Occurring Over the Trial PeriodOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: C21 | Idiopathic Pulmonary Fibrosis | 52 | 2024-03-30actual | — | 2025-05-23 |
| Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PFNCT05330312results2024-09-24Part 1 - Subject Feedback on Functionality and Experience of the dCBT-PF at Week 4Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Digital cognitive behavioral therapy | Pulmonary Fibrosis, Anxiety | 119 | 2023-10-19actual | — | 2024-09-24 |
| First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy SubjectsNCT05427253results2025-01-31Total Number of Treatment Emergent Adverse Events (AEs) and Serious AEs (SAEs)Randomized · Quadruple-masked · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: C106 solution, Placebo | Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | 80 | 2023-06-22actual | — | 2025-01-31 |
| A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 DiabetesNCT05831644results2024-11-12Pharmacodynamic EffectRandomized · Double-masked · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: C21 | Type2diabetes, Endothelial Dysfunction | 11 | 2023-06-16actual | — | 2024-11-12 |
| A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy VolunteersNCT05830799results2025-01-03To Evaluate the Impact of C21 on the Pharmacokinetics (PK) of Caffeine and Paraxanthine (Cmax)Open-label · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Drug Drug Interaction | Drug Interaction | 19 | 2023-05-11actual | — | 2025-01-03 |
| Effect of C21 on Forearm Blood FlowNCT05277922results2025-04-23Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21Non-randomized · Open-label · ScreeningStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: C21, Sodium Nitroprusside | Study Vasodilatory Effects of C21 | 5 | 2022-05-11actual | — | 2025-04-23 |
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642results2023-12-14All-cause Mortality up to Day 60Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: C21, Placebo | COVID-19 | 272 | 2022-04-25actual | — | 2023-12-14 |
| Retrospective Evaluation of Lung Pathology in Subjects With COVID-19NCT04878913observationalAveraged total lung score for both lungs percent measured by per lung percent scores | — | Completed | Drug: C21, Placebo | COVID-19, COVID-19 Pneumonia | 35 | 2021-08-23actual | — | 2024-09-04 |
| Cold Challenge With C21 in RPNCT04388176results2023-05-18Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by ThermographyRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: C21, C21, Placebo, Placebo | Raynaud Phenomenon, Systemic Sclerosis | 20 | 2020-12-14actual | — | 2023-05-18 |
| Safety and Efficacy of C21 in Subjects With COVID-19NCT04452435results2021-04-30Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan: Study Protocol ↗ · Statistical Analysis Plan: Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: C21, Placebo | COVID-19 | 206 | 2020-10-13actual | — | 2021-06-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-21